Fremita Chelsea Fredrick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fremita Chelsea Fredrick has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Rohit Jain
Penn State Milton S. Hershey Medical Center
6 shared publications - Anish Kumar Reddy Meda
Avalon University School of Medicine, Willemstad, Curaçao
4 shared publications Amishi Singla
Dallastown Area High School
2 shared publications- Bhupinder Singh
Government Medical College, Amritsar, India
2 shared publications - Kanishk Aggarwal
Dayanand Medical College and Hospital
2 shared publications Aachal Gupta
Amity Regional High School, Woodbridge, CT 06525, USA
1 shared publication
Latest Publications
- Open Access
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 21 (6) , 1-11
RASopathies and Cardiac Complications: Insights into Mechanisms, Diagnosis, and Innovative Treatments
RAS proteins are critical in cellular signal transduction, influencing cell proliferation, differentiation, and survival. While extensively studied for their role in cancer, RAS gene mutations also contribute significantly to cardiovascular diseases, such as hypertrophic cardiomyopathy, pulmonary valve stenosis, and atrial septal defects. Despite their similar primary structures, RAS proteins exhibit distinct functions in cardiac biology: H-RAS regulates cardiomyocyte size, K-RAS governs proliferation, and N-RAS, less associated with cardiac defects, is understudied in cardiac cells. Congenital RAS mutations, collectively known as RASopathies, include syndromes, like Noonan syndrome and cardio-facio-cutaneous syndrome, which often lead to severe cardiac complications, including heart failure. Genetic testing and imaging advances have improved the diagnosis and management of these conditions. Recent research has shown promise with MEK inhibitors and other targeted therapies, offering potential improvements in managing RAS-related cardiac conditions. This review explores the role of the RAS subfamily in heart disease, highlighting key concepts and potential therapeutic targets. PubMed database was searched using keywords, such as RASopathies, RAS gene mutations, cardiac hypertrophy, cardiovascular disease, RAS/MAPK pathway, congenital heart disease, and more. Relevant literature up to June 2024 was examined and summarized, consisting of data from various clinical trials, metaanalyses, retrospective/prospective cohort studies, and current guidelines.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 21 (6) , 1-11
Open AccessRASopathies and Cardiac Complications: Insights into Mechanisms, Diagnosis, and Innovative Treatments
RAS proteins are critical in cellular signal transduction, influencing cell proliferation, differentiation, and survival. While extensively studied for their role in cancer, RAS gene mutations also contribute significantly to cardiovascular diseases, such as hypertrophic cardiomyopathy, pulmonary valve stenosis, and atrial septal defects. Despite their similar primary structures, RAS proteins exhibit distinct functions in cardiac biology: H-RAS regulates cardiomyocyte size, K-RAS governs proliferation, and N-RAS, less associated with cardiac defects, is understudied in cardiac cells. Congenital RAS mutations, collectively known as RASopathies, include syndromes, like Noonan syndrome and cardio-facio-cutaneous syndrome, which often lead to severe cardiac complications, including heart failure. Genetic testing and imaging advances have improved the diagnosis and management of these conditions. Recent research has shown promise with MEK inhibitors and other targeted therapies, offering potential improvements in managing RAS-related cardiac conditions. This review explores the role of the RAS subfamily in heart disease, highlighting key concepts and potential therapeutic targets. PubMed database was searched using keywords, such as RASopathies, RAS gene mutations, cardiac hypertrophy, cardiovascular disease, RAS/MAPK pathway, congenital heart disease, and more. Relevant literature up to June 2024 was examined and summarized, consisting of data from various clinical trials, metaanalyses, retrospective/prospective cohort studies, and current guidelines.
- 9 July 2025
- Published by Taylor & Francis in Journal of Dietary Supplements
- Vol. 22 (5) , 664-679
Carnitine: Its Crucial Role in Metabolic Health and Cardiovascular Function
Carnitine is an amino acid derivative synthesized from lysine and methionine that is vital for fatty acid metabolism and energy production. Predominantly in its L-form, carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, which is necessary for adenosine triphosphate production. While carnitine deficiency is rare, even among vegetarians, its supplementation could be a promising avenue to address various cardiovascular issues, including ischemia, arrhythmias, and cardiomyopathy. Evidence strongly suggests that carnitine can remarkably improve cardiac function, reduce biomarkers of heart failure, and enhance metabolic profiles in -conditions such as chronic heart failure and myocardial infarction. However, there are concerns about the potential for enlarged trimethylamine-N-oxide levels and atherosclerotic markers with supplementation. This review explores the effects of carnitine supplementation on cardiovascular health, its pathophysiology, and its clinical applications.
- 9 July 2025
- Published by Taylor & Francis in Journal of Dietary Supplements
- Vol. 22 (5) , 664-679
Carnitine: Its Crucial Role in Metabolic Health and Cardiovascular Function
Carnitine is an amino acid derivative synthesized from lysine and methionine that is vital for fatty acid metabolism and energy production. Predominantly in its L-form, carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, which is necessary for adenosine triphosphate production. While carnitine deficiency is rare, even among vegetarians, its supplementation could be a promising avenue to address various cardiovascular issues, including ischemia, arrhythmias, and cardiomyopathy. Evidence strongly suggests that carnitine can remarkably improve cardiac function, reduce biomarkers of heart failure, and enhance metabolic profiles in -conditions such as chronic heart failure and myocardial infarction. However, there are concerns about the potential for enlarged trimethylamine-N-oxide levels and atherosclerotic markers with supplementation. This review explores the effects of carnitine supplementation on cardiovascular health, its pathophysiology, and its clinical applications.
- Open Access
- 5 May 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15 (3) , 23-29
Hollywood and Healthcare: Navigating the Dual Impact of Movies on Public Health
Introduction Synonymous with the American film industry, Hollywood wields considerable influence on public health through its vast global reach and engaging media. This paper explores Hollywood's role and its impacts on public health, primarily driven by its portrayal of healthcare services, illnesses, and related beliefs and provides recommendations to improve “education entertainment” for the future. Methods PubMed was searched using keywords such as hollywood, healthcare, medical dramas, health education, smoking, suicide, and many more. Relevant literature up to June 2024 has been examined and summarized, which consisted of 37 articles with data from various clinical trials, meta-analyses, and literature reviews. Discussion Medical dramas like "Grey's Anatomy" and "E.R." have educated audiences on medical knowledge, healthcare structures, and inspired healthcare career aspirations. By depicting the realities of medical practice, these shows have enhanced public support for healthcare reforms. Similarly, films like "Contagion" have fostered awareness and empathy by positively portraying healthcare professionals during crises. However, Hollywood's glamorization of certain lifestyles has also contributed to body dissatisfaction and unhealthy behaviors, with increased cosmetic procedure rates and eating disorders linked to media portrayals. Furthermore, the depiction of smoking and vaping, as well as the sensationalized portrayal of suicides, has been shown to elevate risky behaviors and suicide rates among impressionable viewers. Conclusions Hollywood's impact on healthcare is thus dual-faceted, necessitating responsible media practices and preventive measures to mitigate adverse outcomes while leveraging its potential for public health education.
- 5 May 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15 (3) , 23-29
Open AccessHollywood and Healthcare: Navigating the Dual Impact of Movies on Public Health
Introduction Synonymous with the American film industry, Hollywood wields considerable influence on public health through its vast global reach and engaging media. This paper explores Hollywood's role and its impacts on public health, primarily driven by its portrayal of healthcare services, illnesses, and related beliefs and provides recommendations to improve “education entertainment” for the future. Methods PubMed was searched using keywords such as hollywood, healthcare, medical dramas, health education, smoking, suicide, and many more. Relevant literature up to June 2024 has been examined and summarized, which consisted of 37 articles with data from various clinical trials, meta-analyses, and literature reviews. Discussion Medical dramas like "Grey's Anatomy" and "E.R." have educated audiences on medical knowledge, healthcare structures, and inspired healthcare career aspirations. By depicting the realities of medical practice, these shows have enhanced public support for healthcare reforms. Similarly, films like "Contagion" have fostered awareness and empathy by positively portraying healthcare professionals during crises. However, Hollywood's glamorization of certain lifestyles has also contributed to body dissatisfaction and unhealthy behaviors, with increased cosmetic procedure rates and eating disorders linked to media portrayals. Furthermore, the depiction of smoking and vaping, as well as the sensationalized portrayal of suicides, has been shown to elevate risky behaviors and suicide rates among impressionable viewers. Conclusions Hollywood's impact on healthcare is thus dual-faceted, necessitating responsible media practices and preventive measures to mitigate adverse outcomes while leveraging its potential for public health education.
- Open Access
- 9 December 2024
- Published by SAGE Publications in Therapeutic Advances in Pulmonary and Critical Care Medicine
- Vol. 19
Bronchiectasis-COPD Overlap Syndrome: A Comprehensive Review of its Pathophysiology and Potential Cardiovascular Implications
Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap Syndrome (BCOS) is a complex pulmonary condition that merges bronchiectasis and chronic obstructive pulmonary disease (COPD), presenting unique clinical challenges. Patients with BCOS typically exhibit a range of symptoms from both conditions, including a chronic productive cough, reduced lung function, frequent exacerbations, and diminished exercise tolerance. The etiology of BCOS involves multiple factors such as genetic predisposition, respiratory infections, tobacco smoke, air pollutants, and other inflammatory mediators. Accurate diagnosis requires a comprehensive approach, incorporating pulmonary function tests to evaluate airflow limitation, radiographic imaging to identify structural lung abnormalities, and blood eosinophil counts to detect underlying inflammation. Treatment strategies are tailored to individual symptom profiles and severity, potentially including bronchodilators, inhaled corticosteroids, and pulmonary therapy to improve lung function and quality of life. Patients with BCOS are also at an increased risk for cardiovascular complications, such as stroke, ischemic heart disease, and cor pulmonale. Additionally, medications like beta-agonists and muscarinic antagonists used in COPD treatment can further affect cardiac risk by altering heart rate. This paper aims to provide a thorough understanding of BCOS, addressing its development, diagnosis, treatment, and associated cardiovascular complications, to aid healthcare providers in managing this multifaceted condition and improving patient outcomes.
- 9 December 2024
- Published by SAGE Publications in Therapeutic Advances in Pulmonary and Critical Care Medicine
- Vol. 19
Open AccessBronchiectasis-COPD Overlap Syndrome: A Comprehensive Review of its Pathophysiology and Potential Cardiovascular Implications
Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap Syndrome (BCOS) is a complex pulmonary condition that merges bronchiectasis and chronic obstructive pulmonary disease (COPD), presenting unique clinical challenges. Patients with BCOS typically exhibit a range of symptoms from both conditions, including a chronic productive cough, reduced lung function, frequent exacerbations, and diminished exercise tolerance. The etiology of BCOS involves multiple factors such as genetic predisposition, respiratory infections, tobacco smoke, air pollutants, and other inflammatory mediators. Accurate diagnosis requires a comprehensive approach, incorporating pulmonary function tests to evaluate airflow limitation, radiographic imaging to identify structural lung abnormalities, and blood eosinophil counts to detect underlying inflammation. Treatment strategies are tailored to individual symptom profiles and severity, potentially including bronchodilators, inhaled corticosteroids, and pulmonary therapy to improve lung function and quality of life. Patients with BCOS are also at an increased risk for cardiovascular complications, such as stroke, ischemic heart disease, and cor pulmonale. Additionally, medications like beta-agonists and muscarinic antagonists used in COPD treatment can further affect cardiac risk by altering heart rate. This paper aims to provide a thorough understanding of BCOS, addressing its development, diagnosis, treatment, and associated cardiovascular complications, to aid healthcare providers in managing this multifaceted condition and improving patient outcomes.
- 2 October 2024
- Published by Taylor & Francis in Future Cardiology
- Vol. 20 (13) , 709-718
Linking hearts and minds: understanding the cardiovascular impact of bipolar disorder
1. Mental health disorders are rising in prevalence worldwide, affecting about 13% of the global population, including anxiety disorder, depressive disorder, intellectual disability, attention defi...
- 2 October 2024
- Published by Taylor & Francis in Future Cardiology
- Vol. 20 (13) , 709-718
Linking hearts and minds: understanding the cardiovascular impact of bipolar disorder
1. Mental health disorders are rising in prevalence worldwide, affecting about 13% of the global population, including anxiety disorder, depressive disorder, intellectual disability, attention defi...
- Open Access
- 31 August 2024
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 39 (3) , 331-340
Critical illness-related corticosteroid insufficiency: latest pathophysiology and management guidelines
Intensive care unit (ICU) admissions in the United States exceed 5.7 million annually, often leading to complications such as post-intensive care syndrome and high mortality rates. Among these challenges, critical illness-related corticosteroid insufficiency (CIRCI) requires emphasis due to its complex, multiple-cause pathophysiology and varied presentations. CIRCI, characterized by adrenal insufficiency during critical illness, presents in up to 30% of ICU patients and may manifest as an exaggerated inflammatory response. Factors such as dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, altered cortisol metabolism, tissue corticosteroid resistance, and drug-induced suppression contribute to CIRCI. Diagnosis is a complex process, relying on a comprehensive assessment including clinical presentation, laboratory findings, and dynamic stimulatory testing. Treatment involves intensive medical care and exacting glucocorticoid therapy. Recent guidelines advocate for individualized approaches tailored to patient presentation and etiology. Understanding the pathophysiology and treatment of CIRCI is vital for clinicians managing critically ill patients and striving to improve outcomes. This research paper aims to explore the latest developments in the pathophysiology and management of CIRCI.
- 31 August 2024
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 39 (3) , 331-340
Open AccessCritical illness-related corticosteroid insufficiency: latest pathophysiology and management guidelines
Intensive care unit (ICU) admissions in the United States exceed 5.7 million annually, often leading to complications such as post-intensive care syndrome and high mortality rates. Among these challenges, critical illness-related corticosteroid insufficiency (CIRCI) requires emphasis due to its complex, multiple-cause pathophysiology and varied presentations. CIRCI, characterized by adrenal insufficiency during critical illness, presents in up to 30% of ICU patients and may manifest as an exaggerated inflammatory response. Factors such as dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, altered cortisol metabolism, tissue corticosteroid resistance, and drug-induced suppression contribute to CIRCI. Diagnosis is a complex process, relying on a comprehensive assessment including clinical presentation, laboratory findings, and dynamic stimulatory testing. Treatment involves intensive medical care and exacting glucocorticoid therapy. Recent guidelines advocate for individualized approaches tailored to patient presentation and etiology. Understanding the pathophysiology and treatment of CIRCI is vital for clinicians managing critically ill patients and striving to improve outcomes. This research paper aims to explore the latest developments in the pathophysiology and management of CIRCI.
- 1 January 2024
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 20 (1) , 1-6
Cardiovascular Manifestations in Inflammatory Bowel Disease
Inflammatory bowel disease is a group of long-term systemic inflammatory disorders affecting the gastrointestinal tract, including Crohn's disease and ulcerative colitis, which may be associated with an increased risk of developing extraintestinal manifestations, including cardiovascular disease, thereby decreasing the quality of life. Pathophysiological changes associated with inflammatory bowel disease include alterations of the microbiome, endotoxemia, and changes to glucose and lipid metabolism. Inflammatory bowel disease patients have higher carotid intima-media thickness, lower flow-mediated dilatation, and increased carotid-femoral pulse wave velocity, which are markers of elevated cardiovascular risk. In addition, inflammatory bowel disease patients are at an increased risk for developing venous and arterial thrombotic events due to a hypercoagulable state caused by thrombocytosis and coagulation system activation. To reduce the risk of developing cardiovascular disease, lifestyle modifications, such as smoking cessation, dietary changes, and increased physical activity alongside management with appropriate medication, should be considered. This research paper examines how inflammatory bowel disease can influence the risk of cardiovascular complications and the involvement of drug therapy. Methods: PubMed was searched using keywords, such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, cardiovascular disease, pericarditis, thromboembolism, and many more. Relevant literature up to March 2023 has been examined and summarized, which consisted of data from various clinical trials, meta-analyses, retrospective/prospective cohort studies, and current guidelines.
- 1 January 2024
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 20 (1) , 1-6
Cardiovascular Manifestations in Inflammatory Bowel Disease
Inflammatory bowel disease is a group of long-term systemic inflammatory disorders affecting the gastrointestinal tract, including Crohn's disease and ulcerative colitis, which may be associated with an increased risk of developing extraintestinal manifestations, including cardiovascular disease, thereby decreasing the quality of life. Pathophysiological changes associated with inflammatory bowel disease include alterations of the microbiome, endotoxemia, and changes to glucose and lipid metabolism. Inflammatory bowel disease patients have higher carotid intima-media thickness, lower flow-mediated dilatation, and increased carotid-femoral pulse wave velocity, which are markers of elevated cardiovascular risk. In addition, inflammatory bowel disease patients are at an increased risk for developing venous and arterial thrombotic events due to a hypercoagulable state caused by thrombocytosis and coagulation system activation. To reduce the risk of developing cardiovascular disease, lifestyle modifications, such as smoking cessation, dietary changes, and increased physical activity alongside management with appropriate medication, should be considered. This research paper examines how inflammatory bowel disease can influence the risk of cardiovascular complications and the involvement of drug therapy. Methods: PubMed was searched using keywords, such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, cardiovascular disease, pericarditis, thromboembolism, and many more. Relevant literature up to March 2023 has been examined and summarized, which consisted of data from various clinical trials, meta-analyses, retrospective/prospective cohort studies, and current guidelines.